Announcement PDF RNS Number : 4019Q N4 Pharma PLC 18 June 2020 N4 Pharma plc ("N4 Pharma", the "Company" or the "Group") Result of General Meeting and grant of warrants N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that at its general meeting held earlier today, all resolutions were duly passed. The results of the proxy voting for the resolutions are set out below. Resolution Votes For* % of votes cast** Votes Against % of votes cast** Total votes cast** Votes withheld** % of issued share capital voted** 1. To authorise the Directors to allot securities. 34,120,538 99.988 4,147 0.0122 34,124,685 0 22.422 2. To disapply statutory preemption 34,115,738 99.985 5,200 0.0152 34,120,938 3,747 22.419 rights***. *Votes "For" include votes giving the Chairman discretion. ** A 'Vote Withheld' is not a vote in law and has not been counted in the calculation of the proportion of the votes 'For' and 'Against' a resolution. *** Proposed as a special resolution. Following the approval of shareholders at today's general meeting, and further to the announcement on 1 June 2020, the Company has now granted warrants over 2,536,562 new ordinary shares to its brokers in respect of the Placing, as announced on 13 May 2020. The warrants are exercisable at a price of 4p until 20 May 2022. Following this grant, the Company has a total of 2,536,562 warrants over ordinary shares outstanding, which represents 1.67 per cent. of the Company's issued share capital as at the date of this announcement. Defined terms within this announcement shall have the meaning as set out in the announcement of 1 June 2020 unless otherwise defined herein. Enquiries: N4 Pharma Plc Nigel Theobald, CEO Via Scott PR Allenby Capital Limited James Reeve/Asha Chotai Tel: +44(0)203 328 5656 Scott PR Georgia Smith Tel: +44(0)1477 539 539 About N4 Pharma N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®. N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END ROMFPMBTMTMBBJM